Orlov Nicole S. Schaeffer net worth and biography

Orlov Nicole Schaeffer Biography and Net Worth

Insider of Insmed

Nicole joined Insmed in October 2012. She brings more than 25 years of experience in Human Resources, organizational development, corporate operations, and building life science organizations. Prior to Insmed, Nicole served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities, and IT functions. At Amicus, Nicole was responsible for the organizational growth and development from its earliest stages to a late-stage clinical company. During this time, she focused on developing a culture of excellence to support that growth. Prior to Amicus, Nicole served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures, a venture capital firm. She has also held HR leadership positions with Oak Industries and EMC Corporation. Nicole received her Bachelor of Arts from the University of Rochester and her Master of Business Administration from Boston University.

What is Orlov Nicole S. Schaeffer's net worth?: The estimated net worth of Orlov Nicole S. Schaeffer is at least $7.05 million as of September 10th, 2024. Ms. Schaeffer owns 100,100 shares of Insmed stock worth more than $7,051,044 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Schaeffer may own. Learn More about Orlov Nicole S. Schaeffer's net worth.
How do I contact Orlov Nicole S. Schaeffer?: The corporate mailing address for Ms. Schaeffer and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Orlov Nicole S. Schaeffer's contact information.
Has Orlov Nicole S. Schaeffer been buying or selling shares of Insmed?: Orlov Nicole S. Schaeffer has not been actively trading shares of Insmed within the last three months. Most recently, Orlov S. Nicole Schaeffer sold 37,575 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a transaction totalling $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares of the company's stock, valued at $7,157,150. Learn More on Orlov Nicole S. Schaeffer's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 534,475 shares worth more than $24,993,111.53. The most recent insider tranaction occured on December, 19th when CEO William Lewis sold 18,750 shares worth more than $1,310,812.50. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 12/19/2024.

Orlov Nicole S. Schaeffer Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/10/2024	Sell	37,575	$71.50	$2,686,612.50	100,100
1/11/2022	Sell	925	$25.11	$23,226.75
11/1/2021	Sell	61,000	$30.28	$1,847,080.00
8/12/2020	Sell	4,465	$28.80	$128,592.00	35,227
6/6/2019	Sell	12,000	$23.24	$278,880.00	36,350
5/30/2018	Sell	25,991	$28.24	$733,985.84	22,253
11/9/2016	Sell	68,774	$11.95	$821,849.30	37,500

Orlov Nicole S. Schaeffer Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $70.44

$68.80

$71.07

50 Day Range

MA: $72.36

$66.29

$76.65

2 Week Range

Now: $70.44

$21.92

$80.53

Volume

5,932,421 shs

Average Volume

2,217,081 shs

Market Capitalization

$12.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.